Two of the remaining three medications, fostamatinib and maraviroc demonstrated transcriptome expression signatures that were negatively correlated with the AD + P PSD protein signature (Signed Jaccard Indexes of −0.0025 and −0.0009, respectively, Supplementary Data 8). This evidence concerns the gene PSD and Alzheimer disease.